Research Funding Opportunities
Pancreatic Cancer Action Early Diagnosis Challenge Award
Applications now open to researchers across the UK.
Awards of up to £40,000 (each) available for research projects with a focus on improving the early diagnosis of pancreatic cancer.
Deadline: 6th July 2015
For more information call 0303 040 1770 or follow the link below:
One 3.5 year PhD studentship in Medicine (Nottingham)
Deconstructing the gut-brain axis in Crohn's disease using fMRI methodology
This fully-funded student will research the appetite dysregulation in intestinal inflammation caused by Crohn's disease. This project will develop MR methods to study brain function in Crohn's disease. These developed methods will be used to study the CNS response to food intake using fMRI in healthy volunteers and patients with Crohn's disease. Findings will be correlated to plasma appetite peptide responses, inflammatory burden, eating behaviour traits and states and clinical measures of satiation. The studentship is fully funded by the Medical Research Council and the Eli and Edythe Broad Foundation Research Program at the Crohn’s and Colitis Foundation of America.
The post will suit a future clinical academic who wants to develop expertise in Inflammatory Bowel Disease, nutrition and eating behaviour; a physiologist who wants to develop expertise in appetite regulation; a food scientist or an MR physicist who wants to develop expertise in fMRI. It will provide truly multi-disciplinary training and a wide portfolio of laboratory, clinical and transferable skills.
Further details of the project, eligibility, funding, supervision and facilities are available below.
Closing date: 30th April 2015. Interviews are likely to be held in mid-May.
- Further information [ 34 kb ]
Bowel & Cancer Research PhD Studentship'15 Call
Call for proposals - EU applicants only
Bowel & Cancer Research is launching a PhD studentship award of up to £75,000 over 3 years. Three awards will be made in November 2015.
Bowel & Cancer Research funds translational research pertaining to diseases of the gastrointestinal tract. For this round funding will be restricted to projects tackling IBS, Ulcerative Colitis and Bowel cancer.
Support will be given to:
- Experimental medicine; studying human disease in human tissue
- Innovation; therapeutic, diagnostic or devices
- Trials; outcomes research
In general the charity does not fund work using experimental animals.
Because of the very strong link between B&CR and the National Centre for Bowel Research and Surgical Innovation, preference will be given to those applications that make some direct use of the facilities of the Centre or demonstrate a strong collaborative approach.
Applications should be returned by 5pm on Friday May 29th.
Final decisions on funding will be made in November.
UEG awards your hard work: Open calls for Research Prize & Lifetime Achievement Award
The UEG Research Prize awards €100.000 for excellence in gastroenterology research and enables the researcher to support future research activities. Follow in the footsteps of Rebecca Fitzgerald and apply until May 18.
Additionally UEG recognises outstanding individuals who have made fundamental contributions to gastroenterology as a whole and UEG in particular with the Lifetime Achievement Award. Nomination closes on April 30.
Researcher-led funding opportunities
The Efficacy and Mechanism Evaluation (EME) Programme is accepting applications to its researcher-led workstream. Applicants are invited to apply by 1pm, 1 July 2015. More information on how to apply can be found on the EME researcher-led call webpage.
EME funding opportunity 15/23 - Mechanisms of action of health interventions
Proposals are sought for translational research into the underlying mechanisms of action of clinical and public health interventions. Studies must utilise patients or samples from current or completed NIHR-funded or NIHR-managed studies in any setting. Proposals will be accepted across a wide range of interventions, including behavioural, pharmaceutical, psychological, surgical and public health interventions. The research should be relevant to the intervention and outcomes proposed by the original study and add significantly to the scientific understanding of the mechanisms of action of the intervention.
The proposed research may involve the analysis or reanalysis of previously stored specimens or data, or the collection of new specimens or new data for additional analysis, provided it is obtained from study participants. Discovery of new biomarkers is not within the remit of the EME Programme.
Applicants will need to make a strong case for how a better understanding of the mechanisms of action will potentially contribute to the future use or development of the technology, future wealth creation and for the ultimate benefit of individual patients’ or the wider NHS
Further details of the commissioning brief are available to download, along with the guidance notes. The deadline for applications is 1pm on 16 June 2015. Potential applicants can register for a webinar taking place on 30 April from 1-1:45pm.
EME funding opportunity 15/19 - Metabolic liver disease (including NAFLD)
Proposals are sought for studies into the diagnosis and treatment of liver disease resulting from metabolic causes, including non-alcoholic fatty liver disease in adults and children. Studies that focus on the early detection of liver disease and those that include mechanistic studies embedded in the main efficacy study are particularly encouraged. Proposals should describe translational research into the clinical efficacy of interventions that have the potential to generate new knowledge, which could be used in the future clinical care of patients.
Applications must concentrate on determining the clinical efficacy of interventions, but the inclusion of embedded hypothesis-driven mechanistic studies within the main clinical evaluation is strongly encouraged. Applications may investigate novel or repurposed interventions and technologies. Studies of incremental or minor improvements to existing technologies or discovery of new biomarkers are not within the remit of the EME programme. Further details of the commissioning brief are available to download, along with the guidance notes. The deadline for applications is 1pm on 16 June 2015. Potential applicants can register for a webinar taking place on 13 April from 12-12:45pm.
EME funding opportunity 15/20 - Pancreatitis
This is a call for proposals to improve the diagnosis and/or treatment of patients with acute or chronic pancreatitis or their sequelae. Applications must concentrate on determining the clinical efficacy of interventions, but the inclusion of embedded hypothesis-driven mechanistic studies within the main clinical evaluation is strongly encouraged. Applications may investigate novel or repurposed interventions and technologies. Studies of incremental or minor improvements to existing technologies or discovery of new biomarkers are not within the remit of the EME programme. Projects must have a strong collaborative approach; the EME Programme is particularly keen to encourage collaboration with small and medium enterprises. Further details of the commissioning brief are available to download, along with the guidance notes. The deadline for applications is 1pm on 16 June 2015. Potential applicants can register for a webinar taking place on 14 April from 13:30-14:15.
EME funding opportunity 15/22 - Very low energy diets for the treatment of obesity and associated conditions
Proposals are sought for efficacy studies into very low energy diets ((VLED1) or diets that are close approximations) for obesity and associated conditions, e.g. Type 2 diabetes. Applications should focus on establishing the efficacy of the dietary intervention as well as its safety and demonstrating the durability of its effects. Diets may be of a sustained or intermittent nature but applications that merely seek to compare weight loss using different diets will not be favoured. The inclusion of a hypothesis-driven mechanistic element is strongly encouraged and all applications will need to justify their proposal in the context of other ongoing trials in the area and make a strong case for how the intervention could be standardised for routine use in the NHS utilising a realistic level of resources. Applications may investigate novel or repurposed interventions and technologies. Studies of incremental or minor improvements to existing technologies or discovery of new biomarkers are not within the remit of the EME programme. Projects must have a strong collaborative approach; the EME Programme is particularly keen to encourage collaboration with small and medium enterprises. Further details of the commissioning brief are available to download, along with the guidance notes. The deadline for applications is 1pm on 16 June 2015. Potential applicants can register for a webinar taking place on 29 April from 11:30 – 12:15.
MRC Biochemical Catalyst: Developmental Pathway Funding Scheme - reminder
The DPFS scheme is a key part of the MRC's Translational Research Strategy and supports the translation of fundamental discoveries toward benefits to human health. It funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including “repurposing” of existing therapies. DPFS is an ongoing scheme, with outline deadlines every 4 months. The next call opens on 11 February 2015 (deadline for outline proposal: 4pm on 25 March 2015, panel meets 20-21 May 2015); the following call opens on 16 June 2015 (deadline for outline proposal: 4pm on 28 July 2015, panel meets 22-23 September 2015). Please note that full submissions to DPFS are by invitation only; submission to the full call is contingent upon prior submission and shortlisting of an outline proposal. Further details are available from the MRC website.
RfPB Competition 27
Research for Patient Benefit Competition 27 will launch on 25 February 2015, with a deadline of 20 May 2015 (1pm deadline). Further details are available on the Competitions page. RfPB is a national, response-mode programme inspired by patients and practice to generate high quality research for the benefit of users of the NHS in England. Its main purpose is to realise, through evidence, the huge potential for improving, expanding and strengthening the way that healthcare is delivered for patients, the public and the NHS.
Proposed research areas for 2014/15 EME commissioned calls - updated 18 Feb 2015
Research in the following broad areas is likely to be commissioned during the next year, although the titles and timings may be subject to change. The individual commissioning briefs, which will be published when the calls open, will define the details of the calls.
Early markers of treatment response: anticipated opening date June 2015
Irritable bowel syndrome: anticipated opening date June 2015
Use of cell therapies: anticipated opening date October 2015
HTA funding opportunity 14/224 - Opioids in chronic nonmalignant pain
The HTA aims to answer the question "What is the effectiveness and cost-effectiveness of discontinuing opioid treatment and instituting alternative drug or non-drug therapies, for patients with chronic non-malignant pain?". The NHS aims to improve outcomes for the millions of people in the United Kingdom who suffer from moderate to severe chronic pain for more than 6 months. It also aims to reduce spending and the number of deaths attributable to prescribed opioids. This is a two-stage application process. Full details of the call and guidance notes are available from the HTA website.
Outline proposals on this topic should be completed using the on-line application form no later than 1pm on 12 May 2015. Applications will be considered by the HTA Commissioning Board at its meeting in July 2015. For shortlisted outline applications, investigators will be given a minimum of eight weeks to submit a full proposal. The full proposal will be considered at the Commissioning Board in November 2015.
HTA commissioned funding opportunity 14/230 - L-ornithine-l-aspartate (LOLA) and/or Rifaximin for acute hepatic encephalopathy in patients with cirrhosis
The HTA will be funding research aiming to answer the question "What is the clinical and cost-effectiveness of L-ornithine-l-aspartate (LOLA) and/or rifaximin in treating acute exacerbations of hepatic encephalopathy in patients with cirrhosis?" Liver disease is a serious health problem in the UK and its prevalence is increasing. Hepatic encephalopathy (HE) is a major symptom of liver failure and is associated with raised levels of ammonia derived primarily from gut bacteria. Most people with severe cirrhosis have a degree of chronic encephalopathy with intermittent acute episodes of overt encephalopathy.
In the UK lactulose is the most used treatment to reduce gut bacterial load; the antibiotic rifaximin has been shown to be effective in smaller trials with few adverse effects but is relatively expensive and may not be cost-effective. A larger trial is needed to confirm this. LOLA acts in a different way, as a substrate for key enzyme systems which metabolise ammonia, and has been shown to be effective in HE compared to placebo in studies mostly with biochemical end-points.
Further studies are needed to evaluate the safety, efficacy, and cost-effectiveness of LOLA compared directly against and in addition to other treatments and with end points based on patient outcomes. Details of the call are available from the HTA website along with guidance notes. The deadline for applications is 12 May 2015, by 1pm.
Proposed research areas for 2015 HTA commissioned calls - updated 9 January 2015
The HTA Programme is considering the following topic areas for future commissioned research. Please note that not all of these topics will ultimately be advertised, but if they are it is likely to be within the next 6 to 12 months. Please also note that topic areas and timings are subject to change. The individual commissioning briefs, which will be published when the call opens, will define the details of the call.
Biomarker-guided antibiotic duration
In patients with major bleeding, is a liberal treatment strategy with early fibrinogen concentrate, or fibrinogen containing plasma products, more effective than a more restrictive strategy
Treatment for people in remission from mild to moderate ulcerative colitis (UC)
The clinical and cost effectiveness of intravenous zoledronic acid in patients with osteoporosis due to alcoholic liver disease
Management of gastroschisis
Quantitative hepatitis B surface antigen assays to determine treatment duration in hepatitis B e-antigen negative disease
Anaesthetic regimens for day-procedure laparoscopic cholecystectomy
Biochemical markers of obstetric cholestasis - this is no longer being considered
What is the effectiveness and cost-effectiveness of oral nutritional support for older malnourished medical and surgical patients after discharge from hospital - this is no longer being considered
HTA researcher-led funding opportunities - updated 09 January 2015
The researcher-led workstream welcomes proposals on topics or research questions identified by researchers within the programme’s remit. The deadline for the next two rounds are 1pm on Wednesday 6 May 2015 and 1pm on Thursday 3 September 2015. Details can be found on the HTA website. Please note that the guidance notes have been updated since the researcher-led call launch in September 2014. Make sure you use the latest version as there have been changes to the advice on technical use of the form and costings for studies.
Pump prime funding for initial feasibility studies
NIHR Enteric HTC aims to identify and address unmet clinical need in the diagnosis and management of disorders of the gastrointestinal tract and bowel function. The HTC seeks new ideas for medical device innovations and offers the opportunity to apply to NIHR Enteric HTC for pump prime funding for initial feasibility studies on potential new medical technologies within the field of digestive diseases and GI surgery.
- Further information[ 33 kb ]
MRC Public Health Intervention Development Scheme (PHIND)
The Public Health Intervention Development scheme (PHIND) is a new MRC funding scheme designed specifically to provide support for early phase development of public health interventions. This rapid response funding scheme is aimed at improving the initial evidence on which the development and evaluation of public health interventions are based. Studies should address an important UK or global public health issue and offer an innovative approach to intervention development or applying an existing intervention in a new setting.
The scheme's remit ranges from primary research developing and designing the intervention to feasibility studies, encompassing:
- developing theory
- modelling process and outcomes
- assessing feasibility
Systematic reviews, meta analyses and pilot studies are outside the remit of the PHIND scheme. Applicants can apply for up to £150K for a maximum of 18 months and the scheme will operate three times a year. For further information, please see the MRC website.
National Institute for Health Research (NIHR) Funding opportunities booklet
This booklet provides information about the NIHR’s research funding and career development opportunities available for researchers based in the NHS, universities, industry and other organisations concerned with health, public health and social care.
A brief overview of the National Institute for Health Research (NIHR)
This leaflet provides an overview of the structure and work of the National Institute for Health Research.
The NIHR has published various documents in which you might be interested. They are available here.